HER2 (Human epidermal growth factor receptor 2), also known as ERBB2, CD340 (cluster of differentiation 340), proto-oncogene Neu, is a membrane tyrosine kinase and has strongest catalytic kinase activity in HER family. Among four HER family proteins, HER2 functions as the most active signaling complex after dimerization with other members. It is encoded by the oncogene ERBB2, which is located at the human chromosome 17q12. HER2 participates in normal cell growth and found on some types of cancer cells. Its amplification is the major pathway causing HER2 receptor overexpression. HER2 is amplified in approximately 15%-20% of breast cancers and functions as the primary driver in breast tumor development and progression. The overexpressed HER2 is regarded as a valuable target in clinic therapeutics. VEGFA (Vascular endothelial growth factor A), also known as VPF, VEGF or MVCD1, is the most potent growth factor for endothelial cells and belongs to the PDGF/VEGF growth factor family. In humans, it is encoded by the VEGFA gene localizing at the chromosome 6p21.1. VEGF-A, as well as VEGF-C, and -D are found in the lung. During the embryonic and pseudoglandular stages, it is expressed in epithelial and mesenchymal compartments, then becoming more restricted to the epithelium as development process. VEGFA encodes a heparin-binding protein existing as a disulfide-linked homodimer. This growth factor is involved in inducing proliferation and migration of vascular endothelial cells. It is essential for physiological and pathological angiogenesis and considered as a powerful vascular permeability-enhancing agent.